ClariVest Asset Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

ClariVest Asset Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-103,300	Closed	-$603K	–	788
2022 Q4	$603K	Sell	103,300 -1,500	-1%	-$7.89K	0.03%	361
2022 Q3	$702K	Hold	104,800	–	–	0.03%	312
2022 Q2	$441K	Buy	+104,800	New	+$415K	0.02%	390
2019 Q2	–	Sell	-31,900	Closed	-$385K	–	770
2019 Q1	$385K	Sell	31,900 -97,306	-75%	-$1.43M	0.01%	474
2018 Q4	$1.62M	Buy	129,206 +20,294	+19%	+$280K	0.03%	336
2018 Q3	$1.62M	Buy	108,912 +2,970	+3%	+$46.7K	0.03%	353
2018 Q2	$1.78M	Sell	105,942 -2,710	-2%	-$52.6K	0.03%	358
2018 Q1	$2.49M	Buy	108,652 +94,334	+659%	+$2.1M	0.04%	309
2017 Q4	$370K	Buy	+14,318	New	+$288K	0.01%	521

ClariVest Asset Management's CNCE Position: Q1 2023 in Review

ClariVest Asset Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 103,300 shares — an estimated $603K sold.

ClariVest Asset Management first reported a position in CNCE in Q4 2017 and held it in 9 quarters. The position peaked at $2.49M in Q1 2018. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

ClariVest Asset Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
ClariVest Asset Management sold 103,300 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $603K.
ClariVest Asset Management first reported a position in Concert Pharmaceuticals, Inc. in Q4 2017 and held it in 9 quarters.
ClariVest Asset Management's Concert Pharmaceuticals, Inc. position peaked at $2.49M in Q1 2018.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on ClariVest Asset Management's 13F filing for Q1 2023, filed 8 May 2023.